Lifestyle-related diseases-visceral obesity, hypertension, dyslipidemia and glucose intolerance-are known to appear in a cluster referred to as metabolic syndrome. As the number of disease components in metabolic syndrome increases in a patient, the structure and function of the heart becomes more compromised. 1) For example, metabolic syndrome increases the risk of atrial enlargement and fibrillation 2, 3) and left ventricular hypertrophy and diastolic dysfunction. 1, 4) These structural and functional abnormalities are considered to contribute to the increased cardiovascular morbidity and mortality associated with metabolic syndrome. However, the mechanisms underlying these abnormalities are not well understood.
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SHRSP.Z-Lepr fa /IzmDmcr rats (SHRSP-fatty) were established by crossing stroke-prone SHR (SHRSP/Izm) with Zucker obese rats to create a new animal model of metabolic syndrome. 5) These rats develop spontaneous severe hypertension and obesity, and exhibit metabolic abnormalities (dyslipidemia, hyperinsulinemia and hyperglycemia), which are similar to those found in human metabolic syndrome. To date SHRSP-fatty have been used in studies that evaluated dysfunction of vasodilation mechanisms, cardiovascular remodeling, and atherogenic dyslipidemia in metabolic syndrome. [6] [7] [8] The aim of the present study was to characterize the cardiac structure and function in SHRSP-fatty. Increased cardiac stiffness induced by disturbed myocardial collagen turnover is suggested as one of the mechanisms of cardiac abnormalities in hypertension and diabetes. 9 ,10) Therefore, as structural parameters, heart weight and a major myocardial collagen, collagen type I, as an index of fibrosis, were measured. Additionally, collagen type III, which contributes to tissue elasticity, was measured and the ratio of type I to type III was calculated as an index of myocardial stiffness. To assess cardiac function in SHRSP-fatty, heart rate, systolic blood pressure, cardiac output, blood flow and stroke volume were measured by tail-cuff and plethysmography, and compared to those in hypertensive lean SHRSP and normotensive lean WistarKyoto rats (WKY). Systolic and diastolic cardiac functions were also determined by echocardiography. The results may inform us whether this model would be a useful animal model to evaluate cardiac complications of metabolic syndrome.
MATERIALS AND METHODS

Experimental Animals
Male SHRSP-fatty (nϭ18), SHRSP (nϭ18) and normotensive control WKY (nϭ18) were purchased at 16 weeks of age from Japan SLC, Inc. (Hamamatsu, Japan). The rats were established by the Disease Model Cooperative Research Association (Hamamatsu, Japan). Standard chow (CE-2; Clea Japan Inc., Tokyo, Japan) and water were available ad libitum during the experimental period. The study protocols were performed according to the Guideline for the Care and Use of Laboratory Animals approved by Mukogawa Women's University.
Tail-Cuff Method and Plethysmography Systolic blood pressure and heart rate of conscious rats were meas- ured by the tail-cuff method using a blood pressure monitor (Model MK-2000, Muromachi Kikai Co., Ltd., Tokyo, Japan). Blood pressure was continuously monitored by photoelectric plethysmography (RBP-100; K&G Co., Ltd., Osaka, Japan) in the tails of conscious rats, and then cardiac output and subcutaneous peripheral blood flow were measured (Continuous blood pressure; K&S Co., Ltd., Osaka, Japan). Stroke volume was calculated from cardiac output and heart rate. The data were expressed as the ratio to body weight, respectively. Transthoracic Echocardiographic Study The rats were anesthetized using ketamine HCl (50 mg/kg, intraperitoneally (i.p.)) and xylazine HCl (10 mg/kg, i.p.), and M-mode left ventricular echograms and Doppler mitral flow were obtained. The ratio of peak mitral early diastolic flow wave (Ewave) velocity to peak mitral flow wave velocity at atrial contraction (A-wave velocity; E/A ratio), the deceleration time of the mitral E-wave velocity (DcT) and mid-wall fractional shortening (FS) were measured to assessment of left ventricular function as described previously. 11, 12) Determination of Contractile Force and Beat Rate in the Isolated Atrial Preparation Under anesthesia with sodium pentobarbital (60 mg/kg, i.p.), the heart was rapidly removed and placed in a Krebs-Henseleit solution (118.4 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO 4 · 7H 2 O, 2.5 mM CaCl 2 · 2H 2 O, 25.0 mM NaHCO 3 , 1.2 mM KH 2 PO 4 and 11.1 mM glucose, pH 7.4). An atrial preparation which consisted of the sino-atrial node and left-right atria was mounted isometrically at an optimal resting tension of 1.0 g in a 20-ml organ bath filled with the Krebs-Henseleit solution. The bath solution was maintained at 34°C and bubbled with a 95% O 2 -5% CO 2 gas mixture. Isometric tension changes were measured with a force-displacement transducer (Model T-7; NEC Sanei Instruments, Ltd., Tokyo, Japan) coupled to a dual channel chart recorder (Model 8K21; NEC San-ei Instruments). Isoproterenol or acetylcholine in the presence of 3 nM isoproterenol were cumulatively added to the bath, and changes in contractile force and beat rate in the atria were recorded. The data were expressed as the changes divided by baseline levels measured before drugs were administered. The negative log EC 50 values were calculated using Graph Pad Prism software (Ver. 4, San Diego, CA, U.S.A.).
Western Blot Study The atrial and left ventricular tissue samples were removed and homogenized in lysis buffer [50 mM Tris-HCl buffer (pH 7.5), containing 0.15 M NaCl, 10 mM ethylenediaminetetraacetic acid (EDTA), 0.1% Tween-20, 0.01% (v/v) protease inhibitor cocktail (Sigma Chemical Co., St. Louis, MI, U.S.A.) and 1 mM dithiothreitol] and centrifuged (10000 rpm) for 15 min at 4°C. Using the supernatant, western blots were performed with antibodies of collagen type I (COL1A2 (M-19); Santa Cruz Biotechnology, Inc., CA, U.S.A., 1 : 1000), collagen type III (COL3A1 (S-17); Santa Cruz Biotechnology, Inc., CA, U.S.A., 1 : 2000), myosin light chain (MLC)-1 (C-18; Santa Cruz Biotechnology, Inc., CA, U.S.A., 1 : 1000) and alpha-sarcomeric actin (Sigma, Missouri, U.S.A., 1 : 20000) and their respective antibodies linked with the appropriate horseradish peroxidasecoupled secondary antibody. Immunoreactive bands were visualized on X-ray film and quantified by NIH-Image program (ver. 1.61). Target-band intensities were expressed relative to alpha-sarcomeric actin-intensity from the same sample.
Determination of Metabolic Parameters and Brain Natriuretic Peptide (BNP) in Blood
Blood was drawn from the abdominal aorta under anesthesia (sodium pentobarbital, 60 mg/kg, i.p.) and non-fasting condition. The serum was separated by centrifugation at 3000 rpm for 10 min at 4°C, and serum levels of total cholesterol, triglyceride, glucose, and insulin were determined using commercial kits; Cholesterol E-test Wako, Triglyceride E-test Wako and Glucose CII-test Wako (Wako Pure Chemical Ind., Ltd., Osaka, Japan) and rat insulin detection kit (Morinaga Biochemistry Lab., Tokyo, Japan). Plasma BNP was measured using a commercial kit (BNP-45 (Rat)-EIA Kit; Phoenix Pharmaceuticals Inc., CA, U.S.A.) according to the manufacturer's instruction.
Data Analysis Data are expressed as meanϮS.E.M. Statistical analysis was performed using analysis of variance (ANOVA) followed by the Bonferroni-Dunn test (Stat View software, Ver. 5.0, Abacus Concepts Inc., CA, U.S.A.). Differences were considered significant at pϽ0.05.
RESULTS
Characteristics
As shown in Table 1 , SHRSP-fatty displayed heavier body weight and higher serum levels of triglycerides, cholesterol, glucose and insulin than those in SHRSP and WKY. The plasma BNP levels in SHRSP-fatty and SHRSP were higher than for WKY.
Heart Weights As an index of cardiac hypertrophy, we compared heart weight in SHRSP-fatty to SHRSP and WKY (Table 1) . Heart weight was normalized by body weight and tibial length, which remains constant after maturity. In condition in which body weight changes, cardiac hypertrophy is more accurately quantified by relating heart weight to tibial length than to body weight.
13) The absolute heart weights and the ratio of heart weight-to-tibial length were significantly increased in both SHRSP-fatty and SHRSP compared to WKY while the ratio of heart weight-to-body weight was significantly smaller in SHRSP-fatty than that in SHRSP. Total atrial weight was significantly increased in SHRSP-fatty compared to SHRSP and WKY. In SHRSP-fatty, the ratio of atrial weight-to-body weight was significantly smaller, while atrial weight-to-tibial length was significantly larger than in SHRSP. Similar to SHRSP, ventricular weight, either normalized to tibial length or not, was significantly heavier in SHRSP-fatty compared to WKY whereas ventricular weight normalized to body weight was significantly decreased. We also measured lung weight as an index of heart failure. There were no significant differences in lung weight, lung weightto-body weight and lung weight-to-tibial length among three groups.
Non-invasive Hemodynamics Systolic blood pressures measured by the tail-cuff method in conscious SHRSP and SHRSP-fatty were markedly higher than for WKY, and the degree of hypertension in SHRSP-fatty was lower than for SHRSP (Table 1) . Heart rates of SHRSP were significantly faster than those of both WKY and SHRSP-fatty (Table 1) . Figure 1 shows cardiac output, subcutaneous peripheral blood flow and stroke volume values in three groups, which were determined using plethysmography. Cardiac output, blood flow and stroke volume were increased in SHRSP-fatty and SHRSP compared to WKY, but there were no significant differences between SHRSP-fatty and SHRSP. In contrast, these parameters normalized by body weight were smaller in SHRSP-fatty than for SHRSP.
Atrial Structure and Functions Collagen type I expressions in atria were increased in SHRSP and SHRSP-fatty compared to WKY, but these increments were not different between SHRSP and SHRSP-fatty (Fig. 2A) . The ratio of collagen type I to type III was increased in atria of SHRSPfatty as similar to SHRSP (Fig. 2B) .
In isolated atrium of SHRSP-fatty, the baseline rate of spontaneous beats was significantly less than WKY, but was similar to SHRSP (Table 1) . SHRSP-fatty heart rate and isolated atrial rate were each correlated inversely with atrial weight (Figs. 2C, D) Fig. 2E ). In contrast, decreased beat rate after In isolated atrium, contractile force in the absence of agonists was smaller in SHRSP-fatty than WKY as similar with SHRSP (Table 1) , but there was no significant difference in changes in contractile force to isoproterenol and acetylcholine among strains (data not shown).
Left Ventricular Structure and Functions Table 2 and Fig. 3 show the echocardiographic parameters describing left ventricular structure, function, and representative mitral flow velocities in WKY, SHRSP and SHRSP-fatty, respectively. Left ventricular diameter increased in both SHRSP and SHRSP-fatty compared to WKY, but there was no significant difference in left ventricular mid-wall FS amongst strains. In contrast, a decrease in mitral E/A ratio and an increase in DcT were observed in SHRSP-fatty compared to WKY and SHRSP.
In ventricles of SHRSP-fatty, protein expressions of both collagen type I were increased compared to WKY and SHRSP (Fig. 4A) . The ratio of collagen type I to type III was significantly increased in ventricle of SHRSP-fatty compared to WKY (Fig. 4B) . MLC-1 expression was decreased in SHRSP-fatty compared to WKY (Fig. 4C ).
DISCUSSION
The results of our study demonstrate the SHRSP-fatty to be a model of metabolic syndrome that exhibits significant cardiac changes including evidence of diastolic dysfunction, increased collagen deposition, reduced heart rate, and atrial hypertrophy. In human, metabolic syndrome has been associated with an increase in heart rate, pulse pressure, enlargement of the left atrium and atrial fibrosis, arterial stiffness, left ventricular hypertrophy, and impairment of left diastolic function. 14) Thus, the SHRSP-fatty rat model reproduces many, but not all, of the phenotype components of metabolic syndrome in humans.
Increasing severity of metabolic syndrome was associated with increasingly compromised structure and function of the heart. 1) For example, metabolic syndrome has been associated with risk of increased atrial size 15, 16) and new onset of atrial fibrillation, which is closely related to atrial enlargement. 2, 3) These findings raise the possibility that metabolic syndrome causes disturbances of not only atrial size, but also atrial pacing function. The atrial enlargement observed in the SHRSP-fatty in this study may represent a response to increased filling pressures associated with left ventricular diastolic dysfunction. The filling pressures would be expected to be even more pronounced at low heart rates, which may explain the negative correlation between atrial enlargement and heart rate in SHRSP-fatty. The heart rate of SHRSP-fatty was similar to that of SHRSP when measured in vitro, suggesting that the intrinsic rate of the sino-atrial pacemaker tissues is similar in the two strains. The lower heart rate of SHRSP-fatty under in vivo conditions suggests that the two strains may differ in their autonomic tone: the SHRSP-fatty having reduced cardiac sympathetic tone (or increased cardiac parasympathetic tone), for example. Effects of obesity and hypertension on the modulation of heart rate by the autonomic nervous system have long been recognized; enhanced sympathetic nervous activity in hypertension, 17, 18) depressed sympathetic nervous activity in obesity, 19, 20) and depressed parasympathetic nervous activity in hypertension and obe- LVIDd, left ventricular end-diastolic diameter; LVIDs, left ventricular end-systolic diameter; FS, mid-wall fractional shortening; E/A ratio, ratio of peak mitral early diastolic flow wave velocity (E-wave) to peak mitral flow wave velocity at atrial contraction; DcT, deceleration time of the mitral E-wave velocity. sity. 21, 22) Further studies are needed to determine the mechanisms underlying the decreased heart rate of SHRSP-fatty, including the possibility of reduced cardiac sympathetic nervous activity.
Our data also suggest that the ventricular diastolic dysfunction observed in SHRSP-fatty occurred independent of increasing ventricular size and increase in blood pressure since diastolic function remained relatively normal in SHRSP despite similar levels of blood pressure and cardiac hypertrophy. These results are consistent with observation that patients with metabolic syndrome have cardiac diastolic dysfunction independent of left ventricular mass 4) and left ventricular hypertrophy, 23) and high blood pressure. 24) Activation of the cardiac renin-angiotensin system, myocardial stiffening associated with fibrosis, and abnormal microvascular function have been suggested as contributing to cardiac diastolic dysfunction in humans and animal models with diabetes and hypertension. 10, 25, 26) We reported that impairment of coronary microcirculation associated with activation of angiotensin type I receptor occurred in SHRSP-fatty. 8) In the present study, we found that collagen type I accumulated in the ventricles along with diastolic dysfunction in SHRSPfatty. Collagen type I confers rigidity while collagen type III contributes to tissue elasticity, and an increase in the ratio of collagen type I to type III is known to be associated with increased myocardial stiffness in hypertensive rats with diastolic heart failure. 27, 28) The ratio of collagen type I to type III was increased in ventricle of SHRSP-fatty. A progressive left ventricular fibrosis associated with myocardial stiffening led to development of ventricular diastolic dysfunction, but not by compensatory or excessive hypertrophy in hypertensive heart. 26) Furthermore, metabolic abnormalities produce enhanced fibrotic responses coincided with a marked increase in end-diastolic pressure, increased left ventricular stiffness, and impaired diastolic filling pattern in Otsuka Long-Evans Tokushima Fatty rats at insulin-resistant prediabetic stage 29) and a diet-induced metabolic syndrome murine model. 30) These findings and our data support the hypothesis that in metabolic syndrome, excess collagen formation in the myocardium was closely associated with ventricular diastolic dysfunction, eventually leading to diastolic heart failure. Recent observations found that matrix metalloproteinases (MMPs) contributed to the progression of chronic heart failure by regulating cardiac extracellular matrix metabolism; e.g. an increased serum MMP-2 level was found in patients with left ventricular systolic and diastolic dysfunction. 9, 31) Interestingly, MMP-2 is activated by peroxynitrite in vitro study, 32) and MMP-2 proteolytic action and myocardial peroxynitrite production was also associated with cardiac dysfunction, resulting from increased degradation of myocardial MLC-1 in an animal model of neonatal asphyxia. 33) MLC-1 is a component of the cardiac contraction protein myosin, and plays an important role in cardiac muscle contraction. Therefore, we investigated changes in MLC-1 expression, and found decreased expression in ventricle of SHRSP-fatty. In previous studies we have proposed that peroxynitrite played a critical role in development of cardiovascular events in SHRSP-fatty. 8, [34] [35] [36] [37] Additional studies are needed to be clarified involvement of MMPs, MLC-1 and peroxynitrite in progression of ventricular diastolic dysfunction in SHRSPfatty.
The plasma BNP level, which is considered to reflect to alterations of ventricular structure and function, was increased in SHRSP-fatty and was similar to that of SHRSP. An elevation of BNP is a hallmark of patients with or at risk of diastolic heart failure among subjects with preserved systolic function independent of left ventricular hypertrophy. 38) Persistently elevated plasma BNP level is not primarily caused by left ventricular diastolic dysfunction itself, but represents a secondary response to the increased filling pressures associated with diastolic dysfunctuon. 39) While the increased BNP observed in SHRSP-fatty confirms the presence of diastolic dysfunction, the lack of any change in lung weight suggests that the diastolic dysfunction was modest, and had not progressed to congestive heart failure.
In conclusion, the present study demonstrated that SHRSP-fatty with metabolic syndrome displayed enlarged, fibrotic cardiac atria and ventricles, reduced heart rates, and ventricular diastolic dysfunction. Regarding possible mechanisms underlying these changes, fibrosis and reduced MLC-1 are expected to have provided an important contribution to the development of diastolic dysfunction. In turn, increased filling pressures associated with diastolic dysfunction would have promoted enlargement of the atria, and this would have been exacerbated in animals with lower heart rates. The SHRSP-fatty rat strain reproduces a number of features of the cardiac phenotype of metabolic syndrome in humans, and may present a useful model to evaluate mechanisms underlying conditions of cardiac dysfunction, especially ventricular diastolic dysfunction in metabolic syndrome.
